During his first year in office, President Trump took no direct action to lower the country’s sky-high prescription drug prices, something that he vowed to tackle during the 2016 campaign. But Trump’s man running the Food and Drug Administration is striving to move the needle in this area with a concentrated push toward expanding generic drug competition.

Continue reading on The Washington Post.